CureVac N.V. has announced a purchase agreement with BioNTech SE, dated June 12, 2025. The agreement outlines the terms and conditions of the acquisition, including actions related to equity awards, the extraordinary general meeting, and post-offer reorganization. Both companies have agreed to issue a joint press release announcing the execution of this agreement. The announcement, made by CureVac N.V., marks a significant development in the collaboration between these two companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.